Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Fineline Cube Dec 22, 2025
Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Fineline Cube Dec 22, 2025
Company Deals

Fosun Pharma Partners with Clavis Bio in $362.5M Strategic Collaboration

Fineline Cube Dec 21, 2025
Company Deals

Leadingtac Raises RMB 200M Series B to Advance Protein Degradation Pipeline

Fineline Cube Dec 20, 2025
Company Deals

Baiyunshan to Acquire Zhejiang Pharma‑Industry for $500.5M, Expanding Distribution Network

Fineline Cube Dec 19, 2025
Policy / Regulatory

China Mandates Specialty Departments in Primary Care by 2030

Fineline Cube Dec 18, 2025
Company Drug

Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT

Fineline Cube Dec 22, 2025
Company Drug

GSK’s Nucala Wins China Approval as First IL‑5 Biologic for COPD

Fineline Cube Dec 22, 2025
Company Drug

Pfizer and BioNTech’s LP.8.1 COVID-19 Vaccine Gets EMA CHMP Nod

Fineline Cube Jul 28, 2025

US giant Pfizer Inc., (NYSE: PFE) and Germany-based BioNTech SE (NASDAQ: BNTX) announced today that...

Company Medical Device

Sansure Biotech’s Gene Polymorphism Detection Kits Receive NMPA Class III IVD Certification

Fineline Cube Jul 28, 2025

China-based Sansure Biotech Inc. (SHA: 688289) announced on July 28, 2025, that it has received...

Policy / Regulatory

NMPA Approves Ambroxol Hydrochloride Oral Drops for Over-the-Counter Sale

Fineline Cube Jul 28, 2025

China’s National Medical Products Administration (NMPA) has approved the switch of ambroxol hydrochloride oral drops...

Company Drug

Biogen’s Zurzuvae Receives Positive CHMP Opinion for Postpartum Depression Treatment

Fineline Cube Jul 28, 2025

US-based Biogen (NASDAQ: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP)...

Others

GSK’s Blenrep Approved in EU for Relapsed or Refractory Multiple Myeloma

Fineline Cube Jul 28, 2025

UK-based GlaxoSmithKline (GSK; NYSE: GSK) announced today that Blenrep has received European Union (EU) approval...

Company Drug

Sanofi’s Sarclisa Approved in EU for Newly Diagnosed Multiple Myeloma

Fineline Cube Jul 28, 2025

France-based Sanofi (NASDAQ: SNY) announced that the European Commission has approved its anti-CD38 monoclonal antibody...

Company Deals

Velavigo Closes $60 Million Pre-A+ Financing Round to Advance Global Clinical Trials

Fineline Cube Jul 28, 2025

Velavigo, a Shanghai-based pharmaceutical startup, has reportedly secured USD 60 million in a Pre-A+ financing...

Company Deals

Matchpoint Therapeutics Partners with Novartis to Develop Oral Covalent Inhibitors for Inflammatory Diseases

Fineline Cube Jul 28, 2025

Matchpoint Therapeutics, a privately held biotechnology company based in Watertown, Massachusetts, announced an exclusive option...

Company Drug

SinoCellTech’s SCT640C Injection Receives NMPA Approval for RA Clinical Trials

Fineline Cube Jul 25, 2025

China-based SinoCellTech Group Ltd (SHA: 688520) announced today that its self-developed product, SCT640C injection, has...

Company Drug

Hengrui Pharmaceuticals’ HRS8179 and HRS-1893 Receive NMPA Clinical Trial Approval

Fineline Cube Jul 25, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced today that it has received clinical...

Company Medical Device

Cryofocus Medtech’s Asthma Cryoablation System Granted FDA Breakthrough Device Designation

Fineline Cube Jul 25, 2025

China-based Cryofocus Medtech (Shanghai) Co., Ltd. (HKG: 6922) announced today that its self-developed asthma cryoablation...

Company Deals

3Sbio and Pfizer Finalize Licensing Agreement for PD-1/VEGF Bispecific Antibody SSGJ-707

Fineline Cube Jul 25, 2025

China-based 3Sbio Inc. (HKG: 1530) announced today that its global licensing agreement with Pfizer Inc.,...

Company

Roche AG Reports 7% Sales Growth in H1 2025, Driven by Pharmaceuticals Expansion

Fineline Cube Jul 25, 2025

Swiss giant Roche AG (SWX: ROG, OTCMKTS: RHHBY) announced its H1 2025 financial results, reporting...

Company Drug

GenFleet Therapeutics Announces Fast Track Designation for GFH375/VS-7375 in Pancreatic Cancer

Fineline Cube Jul 25, 2025

China-based GenFleet Therapeutics announced on July 25, 2025, that its oral KRAS G12D inhibitor, GFH375/VS-7375,...

Company Deals

Leads Biolabs Lists on Hong Kong Stock Exchange in $189 Million IPO

Fineline Cube Jul 25, 2025

China-based Leads Biolabs (HKG: 9887) officially listed on the Main Board of the Hong Kong...

Company Deals

Everest Medicines Completes HK$1.57 Billion Share Placement to Advance R&D and Commercialization

Fineline Cube Jul 25, 2025

China-based Everest Medicines (HKG: 1952) announced today the completion of a share placement of 22,561,000...

Company Drug

Yangtze River Pharmaceutical’s Tadalafil Hydrochloride Tablets Approved for ED Treatment in China

Fineline Cube Jul 25, 2025

China-based Yangtze River Pharmaceutical Group announced on July 25, 2025, that its Class 1 innovative...

Company Drug

Ipsen’s Cabometyx Approved by European Commission for Neuroendocrine Tumors

Fineline Cube Jul 25, 2025

France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that its anticancer drug Cabometyx...

Policy / Regulatory

NHSA Announces Reforms to Centralized Drug Procurement Policies Beyond Lowest Price

Fineline Cube Jul 24, 2025

The National Healthcare Security Administration (NHSA) held a press conference today on the “High-Quality Completion...

Company

Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025

Fineline Cube Jul 24, 2025

Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group...

Posts pagination

1 … 57 58 59 … 600

Recent updates

  • MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED
  • Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal
  • Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT
  • GSK’s Nucala Wins China Approval as First IL‑5 Biologic for COPD
  • EPI-003 Wins FDA IND as First LNP Epigenetic Therapy for Hepatitis B
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

MiniMed Diabetes Files for IPO, Seeking Nasdaq Listing as MMED

Company Deals

Simcere Zaiming Licenses ADC SIM0613 to Ipsen in $1.06 Billion Deal

Company Drug

Merck’s Pimicotinib Wins China Approval as First Class 1 Therapy for TGCT

Company Drug

GSK’s Nucala Wins China Approval as First IL‑5 Biologic for COPD

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.